Diabetes Drug & Cancer Recovery
- A common diabetes medication may offer a new avenue for improving long-term recovery in cancer patients, according to research from the University of East anglia.
- Heart failure, often stemming from cancer itself or chemotherapy, can diminish quality of life, necessitate repeated hospitalizations, and even lead to death.
- The benefits appeared especially pronounced in breast cancer patients undergoing anthracycline chemotherapy, a treatment known to impact heart health.
Diabetes drug shows promise in aiding cancer recovery! New research reveals that SGLT2 inhibitors, typically used for diabetes, could significantly reduce the risk of heart failure in cancer patients and survivors, a frequent complication from cancer treatment. A large-scale study examined the impact of this primary_keyword on cardiovascular health, indicating a reduction of over 50% in heart failure risk. The benefits were especially evident in breast cancer patients undergoing chemotherapy, which improves secondary_keyword outcomes. News Directory 3 brings you the latest on these findings. Further research is planned to confirm these results and explore broader applications of SGLT2 inhibitors. Discover what’s next …
Diabetes Drug Shows Promise in Cancer Patient Heart Health
Updated June 19, 2025
A common diabetes medication may offer a new avenue for improving long-term recovery in cancer patients, according to research from the University of East anglia. The study, involving more than 88,000 cancer patients and survivors, suggests that SGLT2 inhibitors could significantly reduce the risk of heart failure, a frequent complication arising from both cancer and chemotherapy treatments.
Heart failure, often stemming from cancer itself or chemotherapy, can diminish quality of life, necessitate repeated hospitalizations, and even lead to death. The research indicates that SGLT2 inhibitors may lower the risk of heart failure and related unplanned hospital visits by over 50%.
The benefits appeared especially pronounced in breast cancer patients undergoing anthracycline chemotherapy, a treatment known to impact heart health. The research team,comprised of members from the University of East Anglia,Norfolk and Norwich University Hospital,and other international institutions,analyzed 13 studies to reach their conclusions.
vassilios Vassiliou, a professor from UEA’s norwich Medical School and consultant cardiologist at the Norfolk and Norwich University hospital, noted the potential impact. He said the research showed that SGLT2 inhibitors may protect the heart during and after cancer treatment. Vassiliou added that the medications significantly lowered the risk of heart failure and reduced hospital visits related to heart failure.
Researchers observed a notable reduction in hospital admissions for heart failure, with new heart failure cases falling by an estimated 71%. While the findings are promising, the research team emphasized the need for further studies to confirm these results.
What’s next
Further research is planned to solidify these findings, possibly paving the way for routine use of SGLT2 inhibitors in cancer patient care to mitigate heart-related complications.